논문KCI 등재
Correspondence to editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunc tion-associated steatotic liver disease”
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
관련 논문AI추천
Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”Jarell Jie-Rae Tan, May Xuan Goh, Vincent L Chen, Xin En Goh, Yu Jun Wong대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”Dae Won Jun, Eileen Laurel Yoon대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”Jung Hwan Yu, Seung Up Kim대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”전대원, Eileen L. Yoon대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제4호Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”Jung Hwan Yu, Seung Up Kim, Young Eun Chon대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence on Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”김문영, 백순구, Seul Ki Han대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제3호
이 간행물의 다른 논문 (76건)
2025 KASL clinical practice guidelines for management of hepatitis CEun Sun Jang, Eun Ju Cho, Chang Hun Lee, Do Seon Song, Nae-Yun Heo, Jae Yoon Jeong, Jung Gil Park, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jungpp. 1-52Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”Yizi He, Haifeng He, Qi Liang, Yongzhi Xiepp. 1-3Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Mapp. 4-6Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Xiaodi Yang, Zhongqing Qian, Qiong Wang, Fuliang Chen, Xiaojing Wang, Deyan Chenpp. 7-9Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Xinyi Li, Sheng Zhengpp. 10-12